



## ASX Release

### Eastland in First Step to African Funding

**Eastland Medical Systems Ltd (ASX:EMS)** recently announced to Shareholders a Rights Issue to raise \$2.45million. These funds are to be used in the financing of Eastland's forthcoming clinical field trial of its patented sub lingual delivered anti-malaria treatment **ArTiMist™** and the completion of its domestic finance structure.

As a result of several requests from supportive Shareholders that they be given the opportunity to participate in a Rights Issue, the Board have taken this approach to financing the Company and its clinical trials. Eastland is also in an advanced stage to place any shortfall of the Shareholders participation in the Rights Issue.

Eastland's consultants and scientists have recently confirmed their intention to slightly modify the clinical trial and take advantage of a fast track path to the release of the treatment. A smaller modified trial is designed to allow market entry at the earliest time, to begin treatments in children. It also avoids any potential delays through the need to prepare needless extra protocols on this straight forward ethics/trial approval.

As a result of the finding from the Phase I multi and single dose trial clearly establishing a 70% greater bio availability when compared to a tablet treatment have assisted Eastland in its early entry approach and gives **ArTiMist™** considerable clinical support. The significant improvement in bio availability and the more rapid uptake of therapeutic use of the product is the key element to the success of treatment of children, particularly those under two years of age.

**ArTiMist™** has recently been described as an important treatment that will "make a difference" in the success in combating malaria in children, particularly in Africa where a child dies from malaria every 30 seconds.

As a result of extensive meetings in Africa over the past few weeks, Eastland has advanced the process of gaining considerable African support for their **ArTiMist™** project and are confident of securing significant malaria Foundation and investor support in the coming months.

Eastland will continue to update the market on the positive developments over the coming weeks.

#### Further information:

Dermot Patterson  
Chief Executive Officer  
Eastland Medical Systems Ltd  
t: +61 (0) 8 9436 9500  
f: +61 (0) 8 9436 9505  
m: +61 (0) 417 915 511  
[www.eastlandmedical.com.au](http://www.eastlandmedical.com.au)

## Highlights

- Phase 1 Single dose clinical trials for **ArTiMist™** were completed in Malaysian in November 2007 with positive results indicating it is safe to use.
- Phase 1 multi-dose clinical trials for **ArTiMist™** were undertaken in South Africa in February 2008 with positive results indicating the formulation was well tolerated and showed no adverse effects in any of the trial subjects.
- Eastland® now moving to Phase III clinical field trials and regulatory approval.